Biocon on Thursday announced introduction of an advanced novel therapy for the treatment of Hepatitis C in India – CIMIVIR-L.
CIMIVIR-L is a once-a-day oral therapy that the company claims will offer a convenient, effective and safe alternative to people infected with Hepatitis C virus. CIMIVIR-L is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is equivalent of the innovator product commercialised by Gilead Sciences in the US.
The Drugs Controller General of India (DCGI) recentle approved the sale of Sofosbuvir-Ledispasvir combination, which is being manufactured in India under licence from Gilead.
Biocon’s CIMIVIR-L will be made available to patients in India at a a fraction of the global cost of the innovator brand. The cost of a 12-week course of this combination therapy in the US is $94,500 (around Rs 63 lakhs).
Ravi Limaye, president – marketing, Biocon said, “The introduction of CIMIVIR-L will strengthen Biocon’s current porfoli of Virology products. It furthers our commitment to offer affordable therapy of unmet patient needs in debilitating and life-threatening conditions.”
Shares of the company were trading 5.24 per cent up at Rs 507.00 in morning trade.